Skip to main content
Pentixapharm Holding AG logo

Pentixapharm Holding AG — Investor Relations & Filings

Ticker · PTP ISIN · DE000A40AEG0 LEI · 3912005VBOVXNDXEQZ36 F Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2024-10-10 Report Publication Anno…
Country DE Germany
Listing F PTP

About Pentixapharm Holding AG

https://www.pentixapharm.com/

Pentixapharm Holding AG is a clinical-stage company focused on developing first-in-class radiopharmaceuticals. The company's research and development centers on CXCR4 ligand-based compounds for diagnostic and therapeutic applications. Its clinical pipeline features two drug candidates that are ready for Phase III trials. One of its lead assets is the radiodiagnostic candidate 68Ga-PentixaFor, which is being prepared for a Phase 3 study for applications in hypertension. The company's core CXCR4 compound has been extensively studied, administered to over 2,000 patients, and is the subject of more than 150 scientific publications.

Recent filings

Filing Released Lang Actions
Hinweis auf Quartalsfinanzbericht vom 01.07.2024 bis zum 30.09.2024
Report Publication Announcement Classification · 100% confidence The document is a short notification (772 characters) informing stakeholders that a quarterly financial report for the period 01.07.2024 to 30.09.2024 has been published and is available at a specific URL. It does not contain the financial report itself, but rather serves as an announcement of its availability. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2024-10-10 German
Audit Report / Information 2023
Audit Report / Information Classification · 98% confidence The document is titled "Konzernabschluss zum 31. Dezember 2023" (Consolidated Financial Statements as of December 31, 2023) and contains a full set of consolidated financial statements, including the Consolidated Balance Sheet (Konzernbilanz), Consolidated Statement of Comprehensive Income (Konzerngesamtergebnisrechnung), Consolidated Statement of Changes in Equity (Konzerneigenkapitalrechnung), and Consolidated Cash Flow Statement (Konzernkapitalflussrechnung). It also includes a formal 'Bestätigungsvermerk des unabhängigen Abschlussprüfers' (Auditor's Report). This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of an Annual Report (10-K), although this specific document is a German statutory filing (Konzernabschluss) rather than the SEC Form 10-K. Given the options, the closest equivalent for a full, audited annual financial report is '10-K'. The document is clearly the report itself, not an announcement of the report (ruling 2 does not apply). FY 2023
2024-07-05 German

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.